Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Tipos de Cancer / Cánceres Pediátricos / Retinoblastoma / Recursos de NCI
National Cancer Institute®
Ultima Vez Modificado: 1 de mayo del 2002
1
UI - 11399379
AU - Moppett J; Oakhill A; Duncan AW
TI -
Second malignancies in children: the usual suspects?
SO - Eur J Radiol 2001 Jun;38(3):235-48
AD - Department of Paediatric Oncology, Bristol Royal Hospital for Sick
Children, St. Michael's Hill, BS2 8BJ, Bristol, UK.
The aim of this article is to provide an up to date review of second
malignant neoplasms (SMN's) following treatment for childhood cancer,
referring to their incidence, the role of genetic factors, and how the
primary malignancy and treatment received influence the type, site and
prognosis of SMN's. The role of genetic factors will be discussed as far
as they impact upon a predisposition to later development of SMN's. The
primary malignancies that have important associations with SMN's will
then be discussed, in particular Hodgkin's disease, retinoblastoma and
acute lymphoblastic leukaemia. The important second malignancies will be
highlighted, including tumours of the CNS and thyroid, osteosarcoma,
secondary acute myeloid leukaemia and melanoma. Emphasis will be put
upon identifying which patients are most likely to suffer from these
tumours. An important part of the article are case histories. These are
provided in combination with illustrations as a useful adjunct to the
text, with a particular emphasis on radiological features, diagnosis and
screening. Finally, the important but different roles of causal agents,
in particular chemotherapy and radiotherapy are highlighted.
2
UI - 11549509
AU - Haitel A; Wiener HG; Neudert B; Marberger M; Susani M
TI -
Expression of the cell cycle proteins p21, p27, and pRb in clear cell
renal cell carcinoma and their prognostic significance.
SO - Urology 2001 Sep;58(3):477-81
AD - Department of Pathology, University of Vienna, Vienna, Austria.
OBJECTIVES: To determine whether p21, p27, and pRb can predict disease
progression in clear cell renal cell carcinoma. METHODS: The expression
of three negative regulators of the cell cycle, the retinoblastoma gene
product (pRb), the WAF1/Cip1 gene product (p21), and the Kip1 gene
product (p27), was investigated by immunohistochemistry on paraffin
sections from 104 formalin-fixed clear cell carcinoma specimens and
related to p53 overexpression, the clinicopathologic parameters, and
survival. RESULTS: pRb expression was not associated with tumor stage,
but the correlation with p27 and p21 positivity was statistically
significant (r = 0.26, P = 0.008 and r = 0.3, P = 0.002, respectively).
Tumors representing p53 overexpression showed a higher pRb labeling
index compared with p53-negative tumors (P = 0.0004). p21 protein
expression correlated significantly with p27 positivity (r = 0.2, P =
0.04) and was associated with p53 overexpression (P = 0.0005), but did
not correlate with tumor stage or grade. No association could be found
between p27 positivity and tumor grade, tumor stage, or p53
overexpression. In univariate survival analysis, an increased pRb
positivity (P = 0.002) and a low p27 expression (P = 0.0001) predicted a
poor outcome, especially if combined with p53 overexpression (P = 0.004
and P = 0.0002, respectively). p21 did not give any prognostic
information. Moreover, in multivariate analysis, pRb and p27 were
revealed to be statistically significant. CONCLUSIONS: The results of
our study indicate that in clear cell renal cell carcinoma, the cell
cycle proteins p27 and pRb are powerful and independent prognostic
factors and that p21 has no predictive value.
3
UI - 11953594
AU - Fuchs B; Pritchard DJ
TI -
Etiology of osteosarcoma.
SO - Clin Orthop 2002 Apr;(397):40-52
AD - Mayo Clinic, Department of Orthopedics, Rochester, MN 55905, USA.
Although the prognosis and quality of life of patients with osteosarcoma
were improved significantly during the past decades, the pathogenesis
and etiology of this disease remain obscure. Significant interest and
effort in this cancer led to the identification of numerous etiologic
agents. Several chemical agents such as beryllium, viruses such as FBJ,
subsequently found to contain the src-oncogene, and radiation were shown
to be potent inducers of osteosarcoma. Paget's disease, electrical burn,
or trauma all are thought to be other factors that may contribute to the
pathogenesis. More recently, patients with hereditary diseases such as
Rothmund-Thomson syndrome, Bloom syndrome, and Li-Fraumeni syndrome were
found to have an increased risk of having osteosarcoma develop. During
the past few years, the molecular analysis brought a wealth of new
information with numerous genes that were associated with osteosarcoma
and its clinical disease progression. They can be categorized into
self-sufficiency in growth signals, insensitivity to growth inhibitory
signals, evasion of apoptosis, limitless replicative potential,
sustained angiogenesis, and tissue evasion and metastasis. Although the
understanding of these processes in osteosarcoma still is incomplete, it
may have the potential to significantly affect the patient care in the
future.
4
UI - 12011162
AU - Lefevre SH; Chauveinc L; Stoppa-Lyonnet D; Michon J; Lumbroso L; Berthet
TI -
P; Frappaz D; Dutrillaux B; Chevillard S; Malfoy B
A T to C mutation in the polypyrimidine tract of the exon 9 splicing
site of the RB1 gene responsible for low penetrance hereditary
retinoblastoma.
SO - J Med Genet 2002 May;39(5):E21
5
UI - 11980640
AU - Zheng L; Flesken-Nikitin A; Chen PL; Lee WH
TI -
Deficiency of Retinoblastoma gene in mouse embryonic stem cells leads to
genetic instability.
SO - Cancer Res 2002 May 1;62(9):2498-502
AD - Department of Molecular Medicine and Institute of Biotechnology,
University of Texas Health Science Center at San Antonio, San Antonio,
Texas 78245, USA.
Genetic instability has been recognized as a hallmark of human cancers.
Retinoblastoma (Rb) tumor suppressor protein has an essential role in
modulating cell cycle progression. However, there is no direct evidence
supporting its role in maintaining genetic stability. Here, we developed
a sensitive method to examine the level of chromosome instability by
using retrovirus carrying both positive and negative selectable markers
that integrated randomly into individual chromosomes, and the frequency
of loss of this selectable chromosomal marker (LOM) in normal mammalian
cells was measured. Our results showed that normal mouse embryonic stem
(ES) cells had a very low frequency of LOMs, which was less than
10(-8)/cell/generation. In Rb-/- mouse ES cells, the frequency was
increased to approximately 10(-5)/cell/generation, whereas in Rb+/- ES
cells, the frequency was approximately 10(-7)/cell/generation. LOMs was
mediated mainly through chromosomal mechanisms and not through point
mutations. These results, therefore, revealed that Rb, with a
haploinsufficiency, plays a critical role in the maintenance of
chromosome stability. The mystery of why Rb heterozygous carriers have
early-onset tumor formation with high penetrance can be, at least,
partially explained by this novel activity.
6
UI - 11919466
AU - Acikbas I; Keser I; Kilic S; Bagci H; Karpuzoglu G; Luleci G
TI -
Detection of LOH of the RB1 gene in bladder cancers by PCR-RFLP.
SO - Urol Int 2002;68(3):189-92
AD - Department of Medical Biology, Faculty of Medicine, Pamukkale
University, Denizli, Turkey. iacikbas@pamukkale.edu.tr
OBJECTIVES: Retinoblastoma (RB1) gene involves in retinoblastoma,
osteosarcoma, bladder, prostate, lung, breast carcinomas, and soft
tissue sarcomas. Loss of heterozygosity (LOH) is the most common
mutation of the gene. METHODS: Xba I polymorphism in intron 17 of the
gene was used to detect LOH in 20 bladder cancer patients. A cystitis
and an osteosarcoma were used as control. LOH was investigated in three
different kinds of samples (blood, paraffin-embedded tissue and fresh
tissue) belonging to the same patients, and 20 blood samples, 20
paraffin-embedded tissue samples and 16 fresh tissue samples were
obtained from 20 cancer patients. RESULTS: None of the 20 blood samples
showed LOH. Eleven out of 20 paraffin-embedded bladder tissues were
amplified, 3 of them homozygous and all 8 informative paraffin-embedded
tissues showed LOH. Five out of 16 fresh tumor tissues obtained were
amplified, in 1 the fresh tissue was normal, 1 fresh tissue showed LOH
and 3 were not digested by Xba I. CONCLUSION: The results of the study
have suggested that detection of LOH of the RB1 gene by PCR-RFLP can be
a good adjunctive test for evaluation of the bladder cancer. Copyright
2002 S. Karger AG, Basel
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
3D mammography, also known as digital tomosynthesis, is a new technology aimed at having better detection of abnormalities and fewer false positives. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

